We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Reference sheet · Neurodegenerative · CPC catalog code AMYD-015
This sequence carries terminal or reporter modifications (Glp), so no molecular formula or weight is published here — the modified mass must come from the lot certificate of analysis. Residue composition and charge describe the peptide backbone only. Composition figures above are derived arithmetically from the published sequence for the unmodified free peptide. Salt forms (commonly trifluoroacetate or acetate), amidation, and other modifications shift the observed mass — always reconcile against the current lot certificate of analysis.
Volumes for a 1 mg vial of human pyroglutamate (3-40) amyloid at common working concentrations. Add solvent slowly down the vial wall and swirl — do not vortex or shake.
Reference standards in the Neurodegenerative class are typically shipped as lyophilized powder and stored desiccated at −20 °C protected from light. Once reconstituted in bacteriostatic water or the assay-appropriate buffer, aliquot and store at −80 °C to minimize freeze–thaw cycles. Confirm handling requirements against your institutional biosafety and radiation protocols before use.
human pyroglutamate (3-40) amyloid sits within the Neurodegenerative research class (CPC reference AMYD-015). These peptides (amyloid-β, α-synuclein, tau, prion fragments) form ordered β-sheet aggregates and oligomeric species that are used to interrogate seeding, propagation, and cellular toxicity mechanisms of neurodegeneration. Investigators typically incorporate human pyroglutamate (3-40) amyloid as a reference standard, tool ligand, or substrate in the assay contexts listed above. ThT fluorescence, AFM / TEM morphology, and neuronal-toxicity readouts (LDH, MTT).
human pyroglutamate (3-40) amyloid (CPC catalog code AMYD-015) is a synthetic neurodegenerative-disease research peptide in the neurodegenerative category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.
Published and internal research programs use human pyroglutamate (3-40) amyloid as a reference standard in neurodegenerative workflows — for example, aggregation kinetics (tht, ans fluorescence) studies and oligomer- and fibril-mediated toxicity assays. Human clinical evidence is not established.
No. human pyroglutamate (3-40) amyloid is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.
In a neurodegenerative workflow, human pyroglutamate (3-40) amyloid is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. ThT fluorescence, AFM / TEM morphology, and neuronal-toxicity readouts (LDH, MTT).
Other reference standards in the same class — commonly cross-referenced during assay design and comparator selection.